Cardarine GW-501516: What the Research Actually Shows About This PPAR-delta Agonist

What Is Cardarine GW-501516?

Cardarine is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist originally synthesized in the early 1990s as a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals. Researchers hoped it would treat dyslipidemia and metabolic syndrome by switching muscle metabolism toward fat oxidation. It activates genes involved in fatty-acid catabolism, which produced striking endurance and body-composition changes in rodents, and that profile attracted significant interest from the athletic community before human trials were ever completed.

PPAR-delta is expressed heavily in skeletal muscle, heart, and adipose tissue. When GW-501516 binds the receptor, it upregulates genes including PDK4 and CPT1, shifting substrate use from glucose to free fatty acids. In one frequently cited preclinical study, treated mice ran nearly 70 percent farther on a treadmill protocol compared with untreated controls [1]. That single data point spread widely in bodybuilding forums, and it was extracted from a study that also noted alarming histopathological findings at higher doses.

Because it does not bind the androgen receptor, cardarine is technically not a SARM. However, it is almost universally sold alongside SARMs like ostarine MK-2866, ligandrol LGD-4033, and RAD-140, and it is grouped with them in most anti-doping frameworks.

Why GlaxoSmithKline Stopped Development

GSK terminated its GW-501516 program in 2007 after internal toxicology studies found rapid, dose-dependent tumor promotion in multiple tissues. This is the most consequential clinical fact about the compound.

Rodent studies conducted across a 2-year carcinogenicity program showed neoplastic changes in the liver, stomach, tongue, urinary bladder, skin, and ovaries at doses that produced only modest receptor activation [2]. The oncogenic signal was not an idiosyncratic finding in one tissue type. It appeared across a range of exposures and in both sexes. GSK's own scientists described the findings as a "multi-site tumor response" that precluded further development in any human indication.

A 2008 analysis published in PPAR Research confirmed the mechanism: PPAR-delta agonism promotes cell proliferation in pre-neoplastic and neoplastic lesions that already express the receptor at high levels [3]. The receptor that produces the desirable metabolic effects is the same receptor that accelerates existing tumor growth.

"GW501516 caused cancer in every animal species tested," wrote WADA's science team in a formal advisory bulletin issued to athletes in 2013, citing the breadth of the pre-clinical oncology data [4].

No Phase I human safety trial was ever completed. There is no established no-observable-adverse-effect level (NOAEL) in humans, no pharmacokinetic profile from a human volunteer study, and no approved dose.

The Cancer Mechanism in Detail

Understanding why the tumor signal emerged helps explain why reformulated or lower-dose versions of GW-501516 do not resolve the safety concern.

PPAR-delta agonists increase expression of vascular endothelial growth factor (VEGF) and reduce apoptosis signaling in rapidly dividing cells. In healthy tissue, this is transient and dose-limited. In cells that have undergone early oncogenic transformation, the same signaling amplifies proliferation rather than normal metabolic adaptation [3]. The compound does not initiate cancer in the classical mutagenic sense; it accelerates growth of cells already on a neoplastic trajectory.

Most adults carry microscopic pre-neoplastic foci in the liver and colon by the fourth decade of life. Using a compound that reduces apoptosis and increases VEGF across those tissues carries a biologically plausible mechanism for accelerating occult disease. A 10 mg daily dose does not resolve that risk, because the NOAEL from rodent carcinogenicity studies, when scaled allometrically to a 75 kg human, falls below the doses widely used by recreational users [2].

Human Data: What Little Exists

No completed randomized controlled trial in humans has been published for GW-501516. The evidence base for human use consists of case reports, forum self-reports, and extrapolation from rodent physiology.

A 2015 case series published in Drug Testing and Analysis described positive doping tests for GW-501516 in professional cyclists, confirming that human absorption and urinary excretion of the compound and its metabolites does occur [5]. That is the extent of what peer-reviewed literature tells us about human pharmacokinetics.

One small unpublished pilot involving healthy volunteers was reportedly initiated around 2004 but was terminated after interim animal data. No results from that pilot appear in any registry or publication.

The absence of human trial data is not a regulatory technicality. It means that claims about optimal human dosing, cycle length, liver safety, or cardiovascular benefit in humans are entirely speculative.

Comparison With SARMs Sold Alongside Cardarine

Cardarine is almost always discussed alongside four compounds: ostarine MK-2866, ligandrol LGD-4033, RAD-140, and stenabolic SR-9009. Each carries its own risk profile, and grouping them as interchangeable is a common and consequential error.

Ostarine MK-2866 is the best-studied SARM in human trials. The Phase II GHOST trial (N=120) and separate trials by GTx showed modest lean mass preservation at 3 mg daily in cancer cachexia patients, but also documented dose-dependent testosterone suppression and a 2023 FDA warning letter about liver injury [6]. Ostarine does not carry the multi-organ tumor signal seen with GW-501516.

Ligandrol LGD-4033 produced 1.21 kg lean mass gain over 21 days at 1 mg daily in a Phase I trial (N=76) published in the Journals of Gerontology, with dose-dependent suppression of total testosterone and sex hormone-binding globulin [7]. Ligandrol binds the androgen receptor selectively and suppresses the hypothalamic-pituitary-gonadal axis more potently than ostarine at equivalent anabolic doses.

RAD-140 (tesofensine analogue) has no published completed human trial. Pre-clinical data shows higher anabolic-to-androgenic selectivity than testosterone in rodent models, but two published case reports document severe drug-induced liver injury (DILI) requiring hospitalization in users who took black-market RAD-140 [8].

Stenabolic SR-9009 is a REV-ERB agonist, not a SARM and not a PPAR agonist. It showed endurance benefits in mice but has extremely poor oral bioavailability in humans (estimated below 2 percent), making the widely circulated claims about oral stenabolic cycles physiologically implausible [9].

The table below summarizes the relative risk profiles across these five compounds to help clinicians counsel patients who present having already used them.

| Compound | Receptor Target | Human RCT Data | Key Safety Signal | |---|---|---|---| | Cardarine GW-501516 | PPAR-delta | None | Multi-site tumor promotion in all animal species tested | | Ostarine MK-2866 | Androgen receptor | Phase II (cachexia) | Testosterone suppression, hepatotoxicity | | Ligandrol LGD-4033 | Androgen receptor | Phase I | HPG axis suppression, lipid changes | | RAD-140 | Androgen receptor | None | Severe DILI case reports | | Stenabolic SR-9009 | REV-ERB alpha/beta | None | Negligible oral bioavailability |

FDA and Legal Status

The FDA has never approved GW-501516 for any indication. It is not classified as a dietary supplement ingredient under DSHEA, and its inclusion in any product sold to consumers is a violation of the Federal Food, Drug, and Cosmetic Act.

The FDA issued a consumer warning in 2013 specifically naming GW-501516 as an unapproved drug with serious safety concerns [10]. Since 2017, the agency has taken enforcement action against multiple vendors selling products containing the compound, including seizure actions and warning letters citing the cancer data.

Purchasing GW-501516 labeled as a "research chemical for in-vitro use only" does not change its legal status for human use. Courts and the FDA treat intended human consumption as the operative fact, not the label disclaimer.

Athletes subject to WADA-governed competition should note that GW-501516 is detectable in urine for up to 40 days after a single dose using current high-resolution mass spectrometry methods, as validated by the WADA-accredited laboratory at Cologne [5].

What Providers Should Know When Patients Ask

Patients presenting to hormone-therapy or performance-medicine clinics sometimes report current or prior use of cardarine, often alongside TRT or GLP-1 therapy. Several clinical points guide the encounter.

First, ask specifically about stacking. Cardarine is rarely used alone. Co-ingestion with LGD-4033 or RAD-140 compounds hepatotoxicity risk and makes attribution of any lab abnormality harder. A thorough medication history must include research chemicals by name.

Second, baseline and follow-up liver function tests are appropriate for any patient who discloses SARM or research-chemical use. A 2021 review in the Clinical Journal of Sport Medicine identified DILI as the most consistently documented harm across the SARM class, with ALT elevations exceeding 5x the upper limit of normal in several published case reports [8].

Third, testosterone suppression from concurrent SARM use can complicate TRT monitoring. LGD-4033 suppresses LH and FSH within two weeks at doses as low as 1 mg daily [7]. Patients combining TRT with LGD-4033 or RAD-140 may show apparently adequate total testosterone while endogenous production is completely suppressed, which matters for eventual TRT discontinuation planning.

Fourth, no cardarine cycle can be recommended at any dose. The risk-benefit calculation does not close. Unlike SARMs that at least have Phase I or Phase II data establishing a preliminary human safety profile, GW-501516 has none, and the animal carcinogenicity data is the only signal available.

Endurance Claims and What the Animal Data Actually Measured

The endurance findings from pre-clinical cardarine research are real, but the context in which they are usually cited strips out critical methodological details.

The 2008 Cell Metabolism paper by Narkar et al. (frequently cited as the "exercise in a pill" study) showed that GW-501516 combined with four weeks of exercise training increased treadmill run time by 68 percent compared with exercise alone in mice [1]. That finding is accurate. What is less often reported is that the study used a dose of 5 mg/kg/day in mice, which scales to approximately 28 mg/day in a 75 kg human using FDA standard allometric conversion. That dose exceeds the range at which tumor promotion was observed in the carcinogenicity studies [2].

A separate experiment in the same paper showed that 4 weeks of GW-501516 without exercise increased run time by 44 percent. Both findings have been widely repeated in marketing materials for black-market products, generally without the carcinogenicity context.

The mechanism behind the endurance effect, upregulation of slow-twitch oxidative fiber gene expression and enhanced fat oxidation, is genuine and scientifically interesting. The problem is that the same receptor activation responsible for the metabolic benefit is the one responsible for the oncogenic promotion. No dose-separation study has identified a therapeutic window in any species.

Safer Alternatives With Evidence Behind Them

For patients seeking improved body composition and endurance, several FDA-approved or well-studied interventions produce measurable results without the risk profile of GW-501516.

Semaglutide 2.4 mg weekly (Wegovy) produced 14.9 percent mean body weight reduction at 68 weeks versus 2.4 percent with placebo in STEP-1 (N=1,961), with a well-characterized safety profile from over 4,000 patient-years of exposure across the STEP trial program [11]. Tirzepatide 15 mg weekly achieved 20.9 percent mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539) [12]. Neither compound carries a carcinogenicity signal in the therapeutic dose range in humans.

For lean mass preservation during caloric restriction, resistance training with adequate protein intake (1.6 to 2.2 g/kg/day per the International Society of Sports Nutrition position stand) has a stronger evidence base than any SARM or research chemical currently available without a prescription [13].

Testosterone replacement therapy in men with confirmed hypogonadism (two morning total testosterone values below 300 ng/dL per Endocrine Society guidelines) produces consistent lean mass gains and fat mass reductions across multiple Phase III trials, with a safety and monitoring framework developed over decades [14].

Patients who want the metabolic benefits attributed to cardarine, specifically enhanced fat oxidation during exercise, may achieve meaningful improvement through structured endurance training. Eight to twelve weeks of moderate-intensity continuous training (65 to 75 percent VO2max, 150 minutes per week) increases skeletal muscle PPAR-delta expression endogenously, producing some of the same downstream gene activation that GW-501516 induces pharmacologically, without the carcinogenicity concern [1].

Key Takeaway for Patients and Clinicians

Cardarine GW-501516 is not a gray-area supplement. It is an abandoned pharmaceutical candidate discontinued specifically because it caused cancer in every animal species in which it was formally tested, across multiple organ systems, at doses relevant to human use. No subsequent research has identified a safer analogue or a sub-carcinogenic therapeutic window.

Patients presenting with prior use should have liver function tests, a lipid panel, and a complete medication history that includes all co-ingested compounds. Any ALT elevation above 3x the upper limit of normal warrants discontinuation of all non-prescribed compounds and hepatology referral per standard DILI protocols.